[Articles] Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Journal content Created on 16 Jun 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content